Skip to main content

Table 1 Patient characters

From: Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma

Variable All patients (n = 471) Normal bilirubin patients (n = 138)
Agea 60 [26–82] 60 [32–79]
Gender/male (%) 266 (56.5) 65 (47.1)
Pre-operative CA 19-9 level (U/ml)a 199 [5.97–3015.17] 155.8 [11.7–1000]
Pre-operative CA 125 level (U/ml)a 22.5 [1.23–456.2] 22.0 [2.53–171.4]
Pre-operative CEA level (ng/ml)a 3.37 [0.2–113.5] 2.65 [0.2–113.5]
Pre-operative TB level (μmol/l)a 167.5 [1.9–753.1] 27.5 [1.9–34.2]
Pre-operative ALT level (U/l)a 102 [8–772] 86.5 [10–720]
Pre-operative AST level (U/l)a 90 [11–1016] 83 [11–523]
Pre-operative Albumin level (g/l)a 37.2 [18.7–51.8] 38.2 [28.8–50.1]
Tumor size (cm)a 3 [0.8–15] 2.8 [0.8–6]
Preoperative biliary drainage (%) 220 (46.7) 20 (14.5)
Bismuth–Corlette classification (%)
 Type I and II 233 (49.5) 77 (55.3)
 Type III and IV 238 (50.5) 61 (44.2)
T stage (AJCC) (%)
 T1 and T2 218 (46.3) 82 (59.4)
 T3 and T4 253 (53.7) 56 (40.6)
Surgical procedures (%)
 Resected 309 (65.6) 98 (71.0)
 Unresected 162 (34.4) 40 (29.0)
 Postoperative complications (%) 137 (29.1) 32 (23.2)
  1. CA 19-9 carbohydrate antigenic determinant 19-9, CA 125 carbohydrate antigen 125, CEA carcino embryonie antigen, TB total bilirubin, ALT alanine aminotransferase, AST aspartate transaminase, AJCC American Joint Committee On Cancer
  2. aParameters are presented as median and range